Since first described, Thrombotic thrombocytopenic purpura (TTP) has been a very uncommon
disease with a long history marked by periodic episodes in which new evidence and
treatments have markedly changed the course of this once fatal disease. Some of the
most recent developments offer novel and exciting approaches to both our understanding
and management of TTP and indeed, to thrombosis in general. This paper aims to review
some of the significant events leading to the relatively good outcome which patients
can expect today.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.Proc NY Pathol Soc. 1924; 24: 21-24
- An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries.Arch Intern Med. 1925; 36: 89-93
- Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions.Ann Intern Med. 1959; 51: 1409-1419
- Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.Blood. 1977; 50: 413-417
- Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature.Medicine. 1966; 45: 139-159
- and the Members of the CASG. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.N Eng J Med. 1991; 325: 393-397
- Treatment of thrombotic thrombocytopenic purpuras with plasma.N Engl J Med. 1977; 297: 1386-1389
- Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.Br J Haematol. 1996; 94: 383-386
- Anti-CD26 antibodies in thrombotic thrombocytopenic purpura.Br J Haematol. 1994; 88: 816-825
- Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura.Br J Haematol. 1999; 107: 546-555
- Antibodies to von Willebrand Factor-cleaving protease in acute thrombotic thrombocytopenic purpura.N Engl J Med. 1998; 339: 1578-1584
- Von Willebrand Factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.N Engl J Med. 1998; 339: 1578-1584
- Therapy of thrombotic thrombocytopenic purpura: an overview.Semin Thromb Hemost. 1981; 7: 1-14
- Antiplatelet treatment of thrombotic thrombocytopenic purpura.Ann Intern Med. 1977; 86: 102-106
- Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.Am J Hematol. 2005; 78: 49-54
- A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.Blood. 2011; 118: 1746-1753
- A Phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory TTP treated with Rituximab.Br J Haematol. 2015; 170: 208-217
- Absence of viral complications when using Rituximab to treat TTP with plasma exchange.Blood. 2015; 126: 2261
- First-in-human evaluation of anti von Willebrand Factor therapeutic aptamar ARC1779 in healthy volunteers.Circulation. 2007; 116: 2678-2686
- Initial experience from a double- blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.Am J Hematol. 2012; 87: 430-432
- Caplacizumab for acquired thrombotic thrombocytopenic purpura.N Eng J Med. 2016; 374: 511-522
- Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura.N Engl J Med. 2019; 380: 335-346
- Real-world evidence of Caplacizumab in the management of acute TTP.Blood. 2021; 137: 1731-1740
- A regimen with Caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.Blood. 2021; 137: 733-742
- Caplacizumab for acquired thrombotic thrombocytopenic purpura: real-world multicenter data on re-administration and plasma exchange free treatment.Blood. 2022; 140: 8503-8504
- Efficacy of caplacizumab in patients with aTTP in the HERCULES, study according to initial immunosuppression regimen.Blood. 2019; 134: 2365
Article info
Publication history
Published online: March 01, 2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Published by Elsevier Ltd.
